Who makes [14C]JAB-21822?

[14C]JAB-21822 is developed by Allist Pharmaceuticals, Inc..

Last reviewed 2026-04-19 · How we verify

[14C]JAB-21822

Allist Pharmaceuticals, Inc. · Phase 1 active Small molecule

At a glance

Generic name	[14C]JAB-21822
Sponsor	Allist Pharmaceuticals, Inc.
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

[14C]JAB-21822 CI brief — competitive landscape report
[14C]JAB-21822 updates RSS · CI watch RSS
Allist Pharmaceuticals, Inc. portfolio CI